NCT07135973View on ClinicalTrials.gov

A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

March 17, 2028

Conditions
Chronic Graft Versus Host Disease
Interventions
DRUG

Belumosudil

Pharmaceutical form:Tablet-Route of administration:Oral

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT07135973 - A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) | Biotech Hunter | Biotech Hunter